AUTHORS
Yumeng Zhang, MD, Katherine Tobon, PharmD2, Anthony Suda, NP3, Daniel DeAvila Jr, M.S.4, Ling Zhang, MD5, Bijal Shah, MD, MS6, Jose Sandoval-Sus I, MD7, Samuel Benjamin Reynolds, MD8, Supreet Kaur, MD9, Celeste Bello, MD10, Leidy Isenalumhe, MD, MS11, Sameh Gaballa, MD12, Javier Pinilla-Ibarz, MD PhD13, Lubomir Sokol, MD, PhD14
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Introduction
Nodal T-follicular helper (TFH) cell lymphoma carries recurrent mutations in epigenetic regulators, a rationale for hypomethylating therapy. The dual PI3K-delta/gamma inhibitor duvelisib has separate single-agent activity: In the phase 2 PRIMO trial, overall response rate (ORR) was 62% and complete response (CR) rate 51% in angioimmunoblastic T-cell lymphoma (AITL). A phase 1 study of duvelisib plus oral azacitidine reported CR in all 4 patients with a TFH phenotype, but no phase 2 study of that combination has followed. Whether the regimen can be delivered in standard clinical practice is unclear: neither drug is approved for T-cell lymphoma, and the phase 1 azacitidine dose of 100 mg daily is not a marketed tablet strength. We evaluated its efficacy, safety, and implementation.
Methods
We retrospectively reviewed all patients with nodal TFH lymphoma (2022 WHO/ICC) given duvelisib plus azacitidine in standard clinical practice at one academic center from February 2025 to May 2026. Courses on the phase 1 study above were excluded; the 1 rechallenged patient contributed only her rechallenge course. Response was assessed by PET-CT per Lugano 2014 by the treating investigator, adverse events by CTCAE v5.0. Progression-free survival (PFS), overall survival (OS) and duration of response (DOR) were estimated by Kaplan-Meier. Data cutoff July 23, 2026.
Results
Thirteen patients were treated. Median age was 73 years (59-82), 10 (77%) were female and 9 (69%) had ECOG performance status 2-3. Histology was AITL-type in 10, NOS in 2 and follicular-type in 1; 12 of 13 had known stage, all III or IV. Six were primary refractory and 9 (69%) refractory to their last therapy. The median number of prior lines was 1 (1-6); 4 had a prior autologous and none an allogeneic transplant. All 13 were sequenced: TET2 was mutated in 12, DNMT3A in 9, RHOA G17V in 8 and IDH2 R172 in 4.
All 13 started duvelisib at 25 mg twice daily (BID) without a higher lead-in dose. Oral azacitidine is marketed only as 200 mg and 300 mg tablets: 12 started 200 mg on days 1-14, daily in 8 (2,800 mg per cycle, twice the phase 1 dose) and every other day in 4 (1,400 mg, matching phase 1). One of the 12 later switched to subcutaneous azacitidine 42 mg/m2 on days 1-7 for nausea and vomiting; the 13th started subcutaneous 75 mg/m2 after 3 payer denials. A median of 3 cycles (2-10) was given; 5 remain on treatment.
Twelve were evaluable for response. Best ORR was 75% (9 of 12) and the CR rate 67% (8 of 12). At a median follow-up of 8.4 months, median PFS and OS were not reached; PFS was 74% at 6 months and 56% at 12 months, OS 83% and 62%. Median DOR was not reached, with 1 event among 9 responders. Two were bridged to allogeneic transplant in CR, 2 await autologous transplant, 1 declined transplant and 8 were not candidates. Three died, 2 of lymphoma and 1 of malnutrition while in CR.
One patient had stopped the same doublet on trial after 21 cycles while in CR for grade 3 colitis and a rash concerning for DRESS syndrome. Rechallenged off trial 26 months later without dose reduction of either drug, she reached a second CR after 2 cycles and remains in CR at 9 months; neither toxicity recurred.
Grade 3-4 colitis/diarrhea occurred in 2 (15%), grade 3-4 cytopenia in 3 (23%) and grade 3 hypokalemia with acute kidney injury in 1. No grade 3-4 transaminitis or pneumonitis was observed. Serious infection was limited to 1 hospitalization for neutropenic fever and 1 low-level cytomegalovirus reactivation. Duvelisib was dose-reduced in 4 (31%) and azacitidine in 2 (15%); 2 (15%) stopped for toxicity.
Conclusions
In standard clinical practice, duvelisib plus azacitidine produced a 75% ORR and a 67% CR rate in an older, refractory nodal TFH lymphoma population with ECOG 2 or 3 in most patients, and at a median follow-up of 8.4 months, median PFS was not reached. Toxicity was manageable but not negligible: grade 3-4 colitis/diarrhea in 15% leading to toxicity-related discontinuation. Notably, no cases of severe hepatotoxicity or pneumonitis were reported. Both drugs were used off-label and tablet strength, not the trial, set the azacitidine dose. Rechallenge after immune-mediated toxicity was feasible in 1 patient. These encouraging results warrant a dedicated phase 2 trial in nodal TFH lymphoma, with broad eligibility to admit ECOG 2-3 patients.
DISCLOSURES
Yumeng Zhang, MD: Curio Science - Honoraria; Plexus Communications - Honoraria; Acrotech Biopharma - Consultancy (Includes expert testimony); Citius Oncology - Consultancy (Includes expert testimony); ADC Therapeutics - Consultancy (Includes expert testimony); Arima Genomics - Consultancy (Includes expert testimony); Kyowa Hakko Kirin Pharma, Inc. - Consultancy (Includes expert testimony); AbbVie, Inc. - Consultancy (Includes expert testimony)